StockTipsArenaBeta

BUY Dr. Reddy's Laboratories Limited — Kunal Parar, Choice Broking

BUYDr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories share price target & all analyst calls

byKunal Parar, Choice BrokingHorizon: NA (inferred Swing (≤2wk))27 Jul 2026via Zee Business (Live)

Entry₹1,153.7Inferred
Target₹1,190
Total upside +3.15% (call closed)
Stop loss₹1,100-4.65% risk
At expiry₹1,1727 Aug 2026, 3:30 pm
Expired+1.59%auction close
Follow Kunal Parar for new calls(24% target hit, 67 closed calls)Get alertsWatch DRREDDY for new buy/sell callsGet alertsSee 4 active Swing calls on DRREDDYSee 149 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 7 Aug 2026
4 supporting4 neutral3 opposing
Supports the BUY call (4)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·4 Aug · 3d ago

1 advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·3 Aug · 4d ago

Dr. Reddy's Laboratories has received U.S. FDA approval for its rituximab biosimilar. Fresenius Kabi will exclusively commercialize the product in the United States. This approval strengthens Dr. Redd

BSE · Company Update·1 Aug · 6d ago

(opens in new tab)

Dr Reddy's Laboratories Ltd received approval for its gonorrhea drug from Thailand, following a US nod, as reported by Business Standard.

BSE · Company Update·28 Jul · 1w ago

(opens in new tab)
Neutral / worth noting (4)

Dr Reddy’s Srikakulam facility in Andhra Pradesh gets UFDA Form 483 with 3 observations

NewsCnbc-Tv18·30 Jul · 1w ago

(opens in new tab)

Dr. Reddy's Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·22 Jul · 2w ago

(opens in new tab)

Dr. Reddy's Laboratories will release its Q1FY27 financial results on Wednesday, July 22nd, 2026. An earnings call is scheduled for the same day to discuss financial performance.

NSE · Press Release·13 Jul · 4w ago

(opens in new tab)

Dr. Reddy's Laboratories will announce its Q1FY27 financial results on Wednesday, July 22nd, 2026, followed by an earnings call at 19:30 PM IST.

BSE · Company Update·13 Jul · 4w ago

(opens in new tab)
Weighs against the BUY call (3)

Dr. Reddy's Laboratories shares will react to weak Q1 after US-listed ADR falls 10%

NewsCnbc-Tv18·23 Jul · 2w ago

(opens in new tab)

Dr Reddy's Q1 Results: Semaglutide API provision weighs on profit; margin halves

NewsCnbc-Tv18·22 Jul · 2w ago

(opens in new tab)

1 advisor has an active short-term SELL call on this stock

Advisor consensus · adjacent horizon·9 Jul · 4w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Reddy's Laboratories

All analyst calls on Dr. Reddy's Laboratories

More from Kunal Parar, Choice Broking

Every call and its outcome